AxoGen (AXGN) Projected to Post Earnings on Tuesday

AxoGen (NASDAQ:AXGN) is projected to post its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect AxoGen to post earnings of $0.08 per share and revenue of $59.8990 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:00 AM ET.

AxoGen Stock Up 1.9%

Shares of AXGN opened at $33.23 on Tuesday. The company has a quick ratio of 2.64, a current ratio of 4.09 and a debt-to-equity ratio of 0.54. The company has a 50-day moving average price of $32.53 and a two-hundred day moving average price of $23.96. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -664.60 and a beta of 1.00. AxoGen has a 12 month low of $9.22 and a 12 month high of $36.00.

Insiders Place Their Bets

In related news, Director Amy Mcbride Wendell sold 43,684 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $29.31, for a total value of $1,280,378.04. Following the completion of the sale, the director owned 93,826 shares of the company’s stock, valued at $2,750,040.06. This trade represents a 31.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Johnson sold 23,693 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $31.24, for a total transaction of $740,169.32. Following the completion of the transaction, the director owned 13,141 shares of the company’s stock, valued at $410,524.84. This trade represents a 64.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 301,680 shares of company stock valued at $9,174,052 over the last three months. Company insiders own 2.78% of the company’s stock.

Institutional Investors Weigh In On AxoGen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Balyasny Asset Management L.P. lifted its stake in shares of AxoGen by 183.9% during the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock valued at $20,953,000 after acquiring an additional 1,250,968 shares during the period. Wasatch Advisors LP lifted its position in AxoGen by 85.1% during the 2nd quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider’s stock valued at $15,557,000 after purchasing an additional 659,149 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of AxoGen by 1,578.6% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 488,829 shares of the medical equipment provider’s stock valued at $8,721,000 after purchasing an additional 459,707 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of AxoGen by 259.2% in the 2nd quarter. Squarepoint Ops LLC now owns 483,563 shares of the medical equipment provider’s stock valued at $5,247,000 after purchasing an additional 348,950 shares during the last quarter. Finally, Qube Research & Technologies Ltd grew its position in shares of AxoGen by 69.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 728,741 shares of the medical equipment provider’s stock worth $7,907,000 after buying an additional 298,416 shares during the period. 80.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AXGN has been the subject of several analyst reports. JMP Securities set a $34.00 target price on AxoGen in a research report on Thursday, October 30th. Lake Street Capital increased their price objective on AxoGen from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Weiss Ratings restated a “sell (e+)” rating on shares of AxoGen in a research note on Monday, December 29th. Raymond James Financial reaffirmed an “outperform” rating and issued a $36.00 target price on shares of AxoGen in a report on Thursday, December 4th. Finally, HC Wainwright lifted their price target on shares of AxoGen from $26.00 to $39.00 and gave the company a “buy” rating in a report on Friday, December 5th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.56.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.